Returning investor GV returned for a round which hiked the clinical data software provider's overall funding to over $470m.
DNAnexus, a US-based provider of biomedical data analysis software, raised $200m in funding from investors including GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, yesterday.
Alternative investment firm Blackstone’s Growth fund led the round, which also featured Perceptive Advisors, Innovatus Capital Partners, Foresite Capital and Northpond Ventures.
Founded in 2009, DNAnexus operates a cloud-based platform enabling clinical researchers to stores, share, analyse and manage complex clinical data. It claims the platform contains 65 petabytes of data has more than 12,000 users across 48 countries.
The company last raised money in mid-2020 when it hauled in $100m from investors including GV and biotech company Regeneron Pharmaceuticals to take its total funding to $273m. GV also invested in a $68m round in 2019 that included WuXi NextCode, the genome technology subsidiary of pharmaceutical firm WuXi AppTec.
GV had first participated in the company’s $15m series B round…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
